| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIG7 |
| Uniprot No | Q1AHR6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-207aa |
| 氨基酸序列 | MAASRCSGLSEMTLLGSQAVSGLSSPLKSPCQVWNSPSPVCVCVCVCVCVCTRVHMRACSAGSAYLKQMKFCRMAASLDKVKKTDRGERGSCVSTTKRQASLSQRDIPSNNMKLATFPSDVNVESVAASLFFTVMKLGATQLEWNTKTPLGNTSSGFESQLYHSPAIDSEQDLSEVISSQSVETRLTSKVLKVEPESMNAKVFTFKL |
| 预测分子量 | 35.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIG7重组蛋白的参考文献示例(部分基于真实研究，具体细节需核实)：
1. **文献名称**：*MIG7重组蛋白促进肿瘤细胞侵袭的机制研究*
**作者**：Cullen, K.J., et al.
**摘要**：研究揭示了MIG7重组蛋白通过激活基质金属蛋白酶(MMPs)信号通路，增强肿瘤细胞的迁移和侵袭能力，为癌症转移机制提供了新见解。
2. **文献名称**：*MIG7的克隆表达及其在血管生成中的作用*
**作者**：Csiszar, K., et al.
**摘要**：成功克隆并表达MIG7重组蛋白，发现其通过调控内皮细胞迁移和血管生成相关基因，促进肿瘤微环境中异常血管形成。
3. **文献名称**：*重组MIG7蛋白在胃癌中的功能及临床意义*
**作者**：Zhang, Y., et al.
**摘要**：通过体外实验证实MIG7重组蛋白可上调EMT(上皮间质转化)标志物，促进胃癌细胞转移，且其表达水平与患者预后显著相关。
4. **文献名称**：*MIG7重组蛋白作为治疗靶点的体外验证*
**作者**：Li, H., et al.
**摘要**：利用MIG7重组蛋白筛选特异性抗体，证明其抑制肿瘤细胞侵袭的效果，为开发靶向MIG7的癌症疗法提供实验依据。
**注意**：以上文献信息为模拟示例，实际研究中可能存在差异，建议通过PubMed或Web of Science以“MIG7 recombinant protein”或“MIG7 cancer invasion”为关键词检索最新文献。
**Background of MIG7 Recombinant Protein**
MIG7 (Migration-Inducing Gene 7) is a tumor-specific protein initially identified for its role in promoting cancer cell migration, invasion, and metastasis. It was first discovered in studies focusing on endothelial and tumor cell interactions during angiogenesis. MIG7 expression is highly upregulated in various malignancies, including carcinomas of the breast, lung, and colon, but is minimally detected in normal tissues. This selective expression pattern positions MIG7 as a potential biomarker and therapeutic target in oncology.
The MIG7 protein is associated with critical oncogenic processes, such as epithelial-mesenchymal transition (EMT), extracellular matrix remodeling, and evasion of apoptosis. Mechanistically, MIG7 interacts with components of signaling pathways like MAPK/ERK and PI3K/AKT, enhancing cell motility and survival. Its ability to induce lamellipodia formation further underscores its role in metastatic dissemination.
Recombinant MIG7 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research applications. It typically includes tags (e.g., His-tag) for ease of purification and detection. Studies utilizing recombinant MIG7 focus on elucidating its structure-function relationships, validating binding partners, and screening inhibitory compounds.
Current research explores MIG7's utility in diagnostics (e.g., detecting circulating tumor cells) and targeted therapies, such as monoclonal antibodies or small-molecule inhibitors. Its tumor-specific expression reduces off-target effects, making it an attractive candidate for precision medicine. However, challenges remain in fully understanding its regulatory mechanisms and translational potential.
In summary, MIG7 recombinant protein serves as a vital tool in dissecting metastasis-related pathways and advancing anticancer strategies, bridging molecular insights with clinical applications.
×
